Waltham-based Avila Therapeutics Raises $30 Million in Second Round

Waltham, Mass. -- Avila Therapeutics, a Waltham-based emerging biotechnology company, announced on Monday that it has raised $30 million in its second round of venture capital, which was led by The Novartis Option Fund. Other investors in the deal include Abingworth, Advent Venture Partners, Atlas Venture and Polaris Venture Partners. Avila's technology, which was designed to create a range of covalent drug products that fight disease through protein silencing, has demonstrated preclinical activity with two programs, one targeting hepatitis C virus protease and the other targeting Btk, an emerging target in autoimmune disease and certain cancers.
http://www.avilatx.com  |  Jobs at Avila

Note:  At time of posting there were no jobs on the Avila Site.  But that could  change with $30M in funding!